Selecta Biosciences - SELB Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SELB shares.
View SELB analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price objectives for Selecta Biosciences' stock. Their SELB share price forecasts range from $4.00 to $7.00. On average, they expect the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price.
View analysts price targets for SELB or view top-rated stocks among Wall Street analysts.

Selecta Biosciences' stock was trading at $3.26 at the beginning of the year. Since then, SELB shares have decreased by 49.7% and is now trading at $1.64.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our SELB earnings forecast.

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its earnings results on Thursday, August, 4th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.09. The business earned $39.27 million during the quarter, compared to the consensus estimate of $21.45 million. Selecta Biosciences had a net margin of 24.85% and a trailing twelve-month return on equity of 11.30%. During the same period in the prior year, the business posted ($0.04) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Shares of SELB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SELB stock can currently be purchased for approximately $1.64.

Selecta Biosciences (NASDAQ:SELB) has a market capitalization of $250.45 million and generates $85.08 million in revenue each year. The company earns $-25,690,000.00 in net income (profit) each year or $0.01 on an earnings per share basis.

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The official website for the company is selectabio.com. The company can be reached via phone at (617) 923-1400, via email at lstern@soleburytrout.com, or via fax at 617-924-3454.